Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Semprus BioSciences brings in $18mm through its Series B round

Executive Summary

Semprus BioSciences Corp. has raised $18mm through the closing of its Series B venture round. SR One and Foundation Medical Partners co-led the financing (and will each contribute one board member) and were joined by existing investors 5AM Ventures and Pangaea Ventures. The company is developing the Semprus Sustain, which interrupts the way bacteria and blood interact with medical devices to prevent or at least limit complications due to infection and thrombus formation.
Deal Industry
  • Medical Devices
  • Medical Devices
    • Implantable Devices
    • Infection Control-Sterilization
Deal Status
  • Final
Deal Type
  • Financing
    • Venture Financing

Related Companies